Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000390 · ClinicalTrials.gov registry record · Phase 2

Antidepressant Treatment of AIDS Related Depression.

A Phase 2 study of Depression, sponsored by GEIGY Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
1
Study location

NCT00000390: Completed Phase 2 study of Depression, sponsored by GEIGY Pharmaceuticals.

NCT00000390 is a Phase 2 study of Depression that has completed, run by GEIGY Pharmaceuticals. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000390, a Phase 2 study of Depression, has completed, sponsored by GEIGY Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
1
Study location

Study Summary

To test the effectiveness treating AIDS related depression with imipramine hydrochloride. Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status. This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.

Conditions Studied

Depression

Interventions

  • DRUG Imipramine hydrochloride

Study Locations (1)

New York

  • New York Hosp - Cornell Med Ctr - New York

Trial Details

FieldValue
Phase Phase 2
GEIGY Pharmaceuticals

1 total trials

What the finished NCT00000390 record still lists

NCT00000390 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Imipramine hydrochloride is the first listed.

NCT00000390 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00000390 about?

NCT00000390 is a clinical study titled "Antidepressant Treatment of AIDS Related Depression.". To test the effectiveness treating AIDS related depression with imipramine hydrochloride. Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In oth...

What is the current status of trial NCT00000390?

This trial is currently completed. It is a Phase 2 study.

What conditions does trial NCT00000390 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT00000390?

The interventions under investigation include: Imipramine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00000390?

This trial is sponsored by GEIGY Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000390 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00000390, the US trial registry maintained by the National Library of Medicine. NCT00000390 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.